Pacira BioSciences (NASDAQ:PCRX) on Thursday announced that the U.S. Centers for Medicare and Medicaid Services (CMS) issued a product-specific J-code for its non-opioid pain therapy Exparel for ...

Pacira BioSciences PCRX announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel ...

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...

the reversal of lymphopenia and treatment of multiply relapsed locally advanced or metastatic pancreatic cancer Over 100 participants have now received ANKTIVA in cancer prevention trial with goal to ...

PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) ...

Please provide your email address to receive an email when new articles are posted on . Ycanth has received a permanent J-code for the treatment of molluscum contagiosum. The code will be fully ...

Please provide your email address to receive an email when new articles are posted on . Syfovre received a permanent, product-specific J-code, which will go into effect Oct. 1. The code for Syfovre is ...

The aflibercept 8 mg injection improves patient care by allowing longer intervals between treatments, explains Jose A. Martinez, MD, Austin Retina Associates. A new Healthcare Common Procedure Coding ...